Cargando…
Serum KL-6 as a Biomarker of Progression at Any Time in Fibrotic Interstitial Lung Disease
The development of a progressive phenotype of interstitial lung disease (ILD) is still unpredictable. Whereas tools to predict mortality in ILD exist, scores to predict disease progression are missing. The aim of this study was to investigate whether baseline serum KL-6 as an established marker to a...
Autores principales: | Jehn, Lutz B., Costabel, Ulrich, Boerner, Eda, Wälscher, Julia, Theegarten, Dirk, Taube, Christian, Bonella, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917700/ https://www.ncbi.nlm.nih.gov/pubmed/36769819 http://dx.doi.org/10.3390/jcm12031173 |
Ejemplares similares
-
Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPF
por: Bonella, Francesco, et al.
Publicado: (2021) -
Diagnostic approach to interstitial pneumonias in a single centre: report on 88 cases
por: Theegarten, Dirk, et al.
Publicado: (2012) -
Serum KL-6 is a predictor of outcome in pulmonary alveolar proteinosis
por: Bonella, Francesco, et al.
Publicado: (2013) -
Serum KL-6 as a Candidate Predictor of Outcome in Patients with SARS-CoV-2 Pneumonia
por: Kattner, Simone, et al.
Publicado: (2023) -
MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis
por: Bonella, Francesco, et al.
Publicado: (2016)